3D Cell Culture Market Size Set for Significant Growth by 2027

The Global 3D Cell Culture Market is expected to grow at an exponential growth rate of two-to-three percent in 2027. Some of the major factors driving the expansion of the 3D cell culture market include the increasing the demand for organ transplants and tissue engineering with the advancements in scaffold-free technologies and a rise in investment as well as research and development (R&D) funding for cell-based research, growing efforts to find alternatives to testing using animals, increasing rates of chronic illnesses among others.

3D cell culture is an essential method in cell biology and tissue engineering that involves generating and studying cells in an environment that is three-dimensional, emulating the conditions that are found in the human body. It has many advantages that include the ability to reproduce in vivo conditions as well as support the growth of complex multicellular structures and provide realistic situations for testing drugs. Different methods are employed for 3D cell culture, including scaffold-based techniques that utilize materials like hydrogels. Its applications include studies in cancer, tissue engineering as well as drug development resulting in more precise assessments of the effects of drugs. However, it also presents difficulties, such as the complexity, the requirement to have specialized equipment and knowledge as well as higher costs than 2D cell cultures.

Explore market trends, size, share and growth report - request a sample copy: https://meditechinsights.com/3d-cell-culture-market/request-sample/

Advancing 3D Cell Culture Techniques: Meeting the Demands of Modern Research

3D cell culture is a method growing in popularity in the field of cell biology as well as tissue engineering because of several important factors. The first and most important reason is the need for more physiologically accurate cell model models for culture. Traditional 2D culture models often fail to replicate the in vivo environment precisely, resulting in incorrect results in drug testing or disease modeling as well as toxicology studies. Better drug testing is a different factor, since 3D cell cultures provide an excellent method of predicting drug behavior in the human body, possibly cutting down on drug development costs and time-to-market.

Tissue engineering gains a lot from 3D cell cultures, which enables the creation of organs and tissues that are complex to be transplanted and used in research. In the field of cancer research 3D cell culture provides more precise tumour growth and behavior modeling as in comparison to monolayer culture. Additionally stem cell research is aided by 3D culture systems that aid in stem cell differentiation and expansion.

For instance,

In June 2023 Vertex Pharmaceuticals Incorporated and Lonza announced a strategic alliance designed to facilitate the production of Vertex's range of stem cells that are fully specialized, insulin-producing islet cells that are designed for people suffering from Type 1 Diabetes (T1D). The partnership focuses primarily on the VX-880 and VX-264 programs each of which is currently being tested in clinical trials.

In October 2022 Corning Incorporated expanded its 3D cell culture offerings by adding the Elplasia12K flask into the product range. This flask was specifically designed to support spheroid growth which is a method that is commonly used for research into cancer and in the development of treatments for therapeutics.

The development of personalized medicine permits the development of 3D cell-culture models made from the patient's own cells to create personalized treatment and testing. Biomaterials that have been developed like hydrogels and scaffolds, facilitate the design of 3D culture models. Interdisciplinarity among researchers helps to develop 3D cell cultivation techniques.

For instance,

In June 2023 Bristol Myers Squibb received approval from the U.S. Food and Drug Administration (FDA) for commercial production at their newly established manufacturing facility for cell therapy located in Devens, Massachusetts. This facility is an essential component of Bristol Myers Squibb's expanding global network of therapies using cells, which will ensure an ongoing supply of these therapies over the long-term and delivering these treatments to patients around the world with unmet medical needs.

In the month of March, 2021 Thermo Fisher Scientific introduced the Gibco Human Plasma-like Medium (HPLM) which marked the introduction of the first cell-culture medium that resembles the plasma's metabolic characteristics in humans. This unique medium was designed to give researchers an accurate view of cell growth and development within the human body.

Revolutionary Trends in Cell Culture: Organoids and Microfluidics as Catalysts

The use of organoids in 3D cell culture that are more akin to the natural tissue structure as compared to traditional 2D cell cultures, is an important trend due to a variety of reasons. It allows for the modeling of diseases especially in conditions such as neurodegenerative disorders, cancer and gastrointestinal diseases which aids in the study of the progression of disease and testing treatments. Organoids are also increasingly important in drug development and testing providing more precise assessments of safety and efficacy. Additionally, they allow individualized medicine using a patient's own cell which results in more efficient, individualized treatments. Organoids can also aid in understanding the physiology and development of tissues by providing a better understanding of the normal functioning of organs and their development. In addition the use of microtissues and organoids in 3D cell cultivation has the potential to reduce ethical concerns by reducing the need for animal testing in certain instances. The trend is likely to expand as the technology and methods to work with these models of cellular development develop.

For instance,

In July 2023 Thermo Fisher Scientific announced the launch of the Gibco(tm) OncoPro(tm) Tumoroid Culture Medium Kit. This is the first commercially-available culture medium that is specifically developed to support the growth of tumoroids that are derived from patients or cancer organoids, that originate from a variety of types of cancer. Thermo Fisher's revolutionary modular kit aims at making complicated cancer models accessible to scientists, solving these issues and helping to make progress in cancer research.

In the month of February, 2023 Corning Incorporated unveiled its latest advancements in the field of automation as well as 3D cell culture at the annual Society for Laboratory Automation and Screening (SLAS) conference that took place in San Diego, California. In this regard, Corning Life Sciences introduced an range of equipment for 3D cultivation, including the revolutionary Elplasia(r) 12K flask as well as an forthcoming Elplasia plate that is designed with an open-well design to make it easier to manipulate spheroids as well as organoids.

Microfluidic 3D culture is an advanced technique that is used in the field of cell biology as well as tissue engineering. Microfluidics is the process of manipulating small amounts of fluids in micro-scale channels. It has gained attention in cell culture because of the ability of microfluidics to accurately regulate the microenvironment of cells. Microfluidic-based 3D cell culture provides an accurate representation of the cellular environment in vivo which makes them ideal for testing drugs and modeling of disease. Microfluidic systems can be developed to run high-throughput screening of compounds, which is why they are valuable in the development of drugs. Researchers can manage factors like the oxygen concentration, nutrient supply and waste removal precisely using these devices.

Key Constraints/Challenges

The world 3D cell culture market is confronted with many challenges that include the absence of standard protocols for results comparison, the cost of experimenting with equipment that is specialized, and the difficulty of implementing new methods. Scaling up for production on a large scale and making sure biocompatibility is achieved with biomaterials pose additional challenges, in addition to the requirement for reproducible and consistent results. The integration of 3D cells into high-throughput screening as well as complex data analysis presents technical challenges. Solving these problems is essential to ensure the continual expansion and development of applications of 3D cells in a variety of fields, such as the discovery of drugs as well as regenerative medicine and modeling of disease.

North America Accounts for the Largest Share of the Global Market

The market size is different across regions, and there are more established services in developed countries. North America takes the lead followed by Europe and other regions. The driving factors for North America's market include the advanced healthcare infrastructure, the presence of significant players favourable regulatory frameworks, and government support for 3D culture models and the increase in R&D activities due to the increasing number of research institutes and universities are predicted to boost the market.

The Asia Pacific region is anticipated to see the fastest expansion during the forecast time driven by a growing number of chronic illnesses and a flourishing biotechnology industry as well as increased investments by companies in the region due to reduced manufacturing costs, a growing demands for cell therapies and a plethora of research opportunities.

Competitive Landscape

Some prominent players competing in the global 3D cell culture market include Thermo Fisher Scientific, Inc., Merck KGaA, Lonza, Corning Incorporated, Avantor, Inc., PromoCell GmbH, Tecan Trading AG, REPROCELL Inc., CN Bio Innovations Ltd, and Lena Biosciences among others.

Request for TOC and Competitive Analysis: https://meditechinsights.com/3d-cell-culture-market/

Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in the Market

Players operating in this market are adopting both organic and inorganic growth strategies such as enhancing manufacturing capabilities, collaborations, and acquisitions to garner market share. For instance,

In July 2023, Merck announced a €23 million investment to expand its cell culture media production in Kansas, USA. The expansion includes the addition of 9,100 square meters of lab space and improved production capabilities

In November 2022, FUJIFILM Corporation announced a substantial investment of $188 million to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA. The facility will encompass more than 250,000 square feet on 64 acres to meet the growing market demand and focus on the production of animal component-free, dry powder, and liquid media to support bioproduction and advanced therapies, contributing to the advancement of life science and healthcare research and development.

The market is expected to continue to grow due to increased demand for personalized medicine, rising adoption of 3D cell cultures in cancer research, the need for more accurate and physiologically relevant models in various fields of research and application, technological innovations, and aggressive organic and inorganic growth strategies followed by the players.

Key Strategic Questions Addressed

What is the market size & forecast for the Global 3D Cell Culture Market?
What are the historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the Global 3D Cell Culture Market?
How has COVID-19 impacted the Global 3D Cell Culture Market?
What are the major growth drivers, restraints/challenges impacting the market?
What are the opportunities prevailing in the market?
What is the investment landscape?
Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
Who are the major players operating in the market? What is the competitive positioning of key players?
Who are the new players entering the market?
What are the key strategies adopted by players?

Find more related report:

Cell-Based Assays Market: https://meditechinsights.com/cell-based-assays-market/

Cell Analysis Market: https://meditechinsights.com/cell-analysis-market/

Cell and Gene Therapy CDMO Market: https://meditechinsights.com/cell-and-gene-therapy-cdmo-market/

Contact:

Ruta Halde
Associate, Medi-Tech Insights
Phone: +32 498 86 80 79
Email: info@meditechinsights.com
Website: https://meditechinsights.com/

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

This release was published on openPR.